| BIOGEN INC. DL -,0005 |
| USA |
| Gesundheit |
| US09062X1037 / 789617 |
| IDP (Frankfurt) / BIIB (NASDAQ) |
| FRA:IDP, ETR:IDP, IDP:GR, NASDAQ:BIIB |
| S&P500 |
| https://www.biogen.com/ |
|
Biogen Inc. is a biotechnology company focused on discovering, developing, and delivering therapies for serious neurological, neurodegenerative, and rare diseases. Biogen’s current portfolio includes treatments for multiple sclerosis, Alzheimer’s..
>Volltext.. |
| 27723.37 Mio. EUR |
| 33909.42 Mio. EUR |
| 8412.01 Mio. EUR |
| 2373.83 Mio. EUR |
| 726.67 Mio. EUR |
| 4.94 EUR |
| 7274.63 Mio. EUR |
| 1118.83 Mio. EUR |
| 2506.52 Mio. EUR |
| 0.33 |
| 3.69% |
| -43.76% |
| - |
| - |
| - |
| - |
| BIOGEN |
| 22.09.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|